Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business
SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.